Next Article in Journal
Advantages of Using Paclitaxel in Combination with Oncolytic Adenovirus Utilizing RNA Destabilization Mechanism
Next Article in Special Issue
Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases
Previous Article in Journal
Methylation-Based Signatures for Gastroesophageal Tumor Classification
Previous Article in Special Issue
Contribution of Macrophages and T Cells in Skeletal Metastasis
Open AccessArticle

A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers

1
Department of Oral and Maxillofacial Surgery, Shimane University Faculty of Medicine, Shimane 693-8501, Japan
2
Department of Oral and Maxillofacial Surgery, Matsue City Hospital, Shimane 690-8509, Japan
3
Department of Oncology/Hematology and Innovative Cancer Center, Shimane University Hospital, Shimane 693-8501, Japan
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(5), 1209; https://doi.org/10.3390/cancers12051209
Received: 20 April 2020 / Revised: 8 May 2020 / Accepted: 10 May 2020 / Published: 12 May 2020
(This article belongs to the Special Issue Targeting Bone Metastasis in Cancers)
This single-center retrospective observational study aimed to identify risk factors for developing denosumab-related osteonecrosis of the jaw (DRONJ) in stage IV solid cancer patients with bone metastases. In total, 123 consecutive patients who had received 120 mg of denosumab every 4 weeks at least twice between July 2014 and October 2018 were included. We surveyed their demographics, medical history, blood test, underlying disease, and intraoral findings. Fourteen patients (11.4%) developed DRONJ within a mean denosumab administration period of 4 months (range: 2–52 months). Univariate analyses showed a statistically significant correlation between DRONJ and hormone therapy, chemotherapy/molecular target drug, apical periodontitis, periodontal disease, sex and body mass index. Multivariate analysis showed a statistically significant correlation between DRONJ and hormone therapy (odds ratio [OR], 22.07; 95% confidence interval [CI], 2.86–170.24), chemotherapy and/or molecular targeted therapy (OR, 18.61; 95% CI, 2.54–136.27), and apical periodontitis (OR, 22.75; 95% CI, 3.20–161.73). These findings imply that collaborative oral examinations by oral specialists may reduce the risk of development of DRONJ in patients treated with denosumab for bone metastases from solid cancers. View Full-Text
Keywords: denosumab-related osteonecrosis of the jaw; bone metastasis; denosumab; retrospective cohort study denosumab-related osteonecrosis of the jaw; bone metastasis; denosumab; retrospective cohort study
Show Figures

Figure 1

MDPI and ACS Style

Okuma, S.; Matsuda, Y.; Nariai, Y.; Karino, M.; Suzuki, R.; Kanno, T. A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers. Cancers 2020, 12, 1209.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop